PT  - JOURNAL ARTICLE
AU  - Jonathan A. Ledermann
TI  - Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis?
AID  - 10.1097/IGC.0b013e318217b30b
DP  - 2011 May 01
TA  - International Journal of Gynecologic Cancer
PG  - S9--S11
VI  - 21
IP  - Supp 1
4099  - http://ijgc.bmj.com/content/21/Supp_1/S9.short
4100  - http://ijgc.bmj.com/content/21/Supp_1/S9.full
SO  - Int J Gynecol Cancer2011 May 01; 21
AB  - There is some evidence from in vitro studies as well as case series that patients with documented platinum resistance will respond to platinum after a nonplatinum drug. In addition, retrospective case studies have demonstrated the difficulty in determining if delaying second platinum is detrimental or beneficial. For that reason, a prospective Italian randomized trial conducted by the Multicenter Italian Trials in Ovarian Cancer (MITO) Group (MITO-8), comparing nonplatinum with platinum-based therapy is being performed to assess the effects of delaying platinum on survival.